Literature DB >> 25592074

Procalcitonin and long-term prognosis after an admission for acute heart failure.

Maria Pilar Villanueva1, Anna Mollar2, Patricia Palau3, Arturo Carratalá1, Eduardo Núñez2, Enrique Santas2, Vicent Bodí2, Francisco J Chorro2, Gema Miñana4, Maria L Blasco5, Juan Sanchis2, Julio Núñez2.   

Abstract

BACKGROUND: Traditionally, procalcitonin (PCT) is considered a diagnostic marker of bacterial infections. However, slightly elevated levels of PCT have also been found in patients with heart failure. In this context, it has been suggested that PCT may serve as a proxy for underrecognized infection, endotoxemia, or heightened proinflammatory activity. Nevertheless, the clinical utility of PCT in this setting is scarce. We aimed to evaluate the association between PCT and the risk of long-term outcomes. METHODS AND
RESULTS: We measured at admission PCT of 261 consecutive patients admitted for acute heart failure (AHF) after excluding active infection. Cox and negative binomial regression methods were used to evaluate the association between PCT and the risk of death and recurrent rehospitalizations, respectively. At a median follow-up of 2years (IQR: 1.0-2.8), 108 deaths, 170 all-cause rehospitalizations and 96 AHF-rehospitalizations were registered. In an adjusted analysis, including well-established risk factors such as natriuretic peptides and indices of renal function, the logarithm of PCT was associated with a higher risk of death (HR=1.43, CI 95%: 1.12-1.82; p=0.004), all-cause rehospitalizations (IRR=1.22, CI 95% 1.02-1.44; p=0.025) and AHF-rehospitalizations (IRR=1.28, CI 95%: 1.02-1.61; p=0.032). The association with these endpoints persisted after adjustment for other inflammatory biomarkers such as white blood cells, C-reactive protein and interleukins.
CONCLUSION: In patients with AHF and no evidence of infection, PCT was independently and positively associated with the risk of long-term death and recurrent rehospitalizations.
Copyright © 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Heart failure; Procalcitonin; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 25592074     DOI: 10.1016/j.ejim.2014.12.009

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  5 in total

Review 1.  The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers.

Authors:  Marin Nishimura; Alison Brann; Kay-Won Chang; Alan S Maisel
Journal:  Curr Heart Fail Rep       Date:  2018-08

Review 2.  Redefining biomarkers in heart failure.

Authors:  Michele Correale; Ilenia Monaco; Natale Daniele Brunetti; Matteo Di Biase; Marco Metra; Savina Nodari; Javed Butler; Mihi Gheorghiade
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

Review 3.  The role of procalcitonin in acute heart failure patients.

Authors:  Martin Möckel; Julia Searle; Alan Maisel
Journal:  ESC Heart Fail       Date:  2017-07-18

4.  Procalcitonin (PCT) Predicts Worse Outcome in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF).

Authors:  J Banach; Ł Wołowiec; D Rogowicz; L Gackowska; I Kubiszewska; W Gilewski; J Michałkiewicz; W Sinkiewicz
Journal:  Dis Markers       Date:  2018-08-28       Impact factor: 3.434

5.  Low-Level Elevations of Procalcitonin Are Associated with Increased Mortality in Acute Heart Failure Patients, Independent of Concomitant Infection.

Authors:  Fabrice F Darche; Moritz Biener; Matthias Müller-Hennessen; Rasmus Rivinius; Kiril M Stoyanov; Barbara R Milles; Hugo A Katus; Norbert Frey; Evangelos Giannitsis
Journal:  Life (Basel)       Date:  2021-12-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.